Evercore ISI Group Downgrades Legend Biotech to In-Line, Announces $20 Price Target

Benzinga · 2d ago
Evercore ISI Group analyst Umer Raffat downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to In-Line and announces $20 price target.